-
XFOR Dashboard
- Financials
- Filings
-
Holdings
- Transcripts
- ETFs
- Insider
- Institutional
- Shorts
X4 Pharmaceuticals (XFOR)
Company Profile
Quarter (USD) | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 98.20 mm | 98.20 mm | 98.20 mm | 98.20 mm | 98.20 mm | 98.20 mm |
Cash burn (monthly) | 16.60 mm | 2.87 mm | 12.23 mm | 1.90 mm | 11.34 mm | 13.27 mm |
Cash used (since last report) | 66.76 mm | 11.53 mm | 49.18 mm | 7.63 mm | 45.63 mm | 53.39 mm |
Cash remaining | 31.44 mm | 86.67 mm | 49.02 mm | 90.57 mm | 52.57 mm | 44.81 mm |
Runway (months of cash) | 1.9 | 30.2 | 4.0 | 47.7 | 4.6 | 3.4 |
13F holders | Current |
---|---|
Total holders | 105 |
Opened positions | 13 |
Closed positions | 13 |
Increased positions | 34 |
Reduced positions | 18 |
13F shares | Current |
---|---|
Total value | 66.59 bn |
Total shares | 143.83 mm |
Total puts | 50.60 k |
Total calls | 213.40 k |
Total put/call ratio | 0.2 |
Largest owners | Shares | Value |
---|---|---|
Bain Capital Life Sciences Fund | 16.92 mm | $0.00 |
Bain Capital Life Sciences Investors | 16.92 mm | $11.32 bn |
Growth Equity Opportunities 18 VGE | 15.74 mm | $30.54 mm |
NEA Management | 14.99 mm | $10.04 bn |
BlackRock | 11.21 mm | $7.50 bn |
Vanguard | 8.44 mm | $5.65 bn |
Orbimed Advisors | 7.13 mm | $4.77 bn |
Kingdon Capital Management, L.L.C. | 4.64 mm | $3.10 bn |
Empery Asset Management | 4.55 mm | $0.00 |
Adage Capital Partners GP, L.L.C. | 4.28 mm | $2.86 bn |
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
24 Jan 25 | Mary DiBiase | Common Stock | Sell | Dispose S | No | Yes | 0.4535 | 22,258 | 10.09 k | 490,980 |
24 Jan 25 | Ragan Paula | Common Stock | Sell | Dispose S | No | Yes | 0.454 | 76,473 | 34.72 k | 1,087,386 |
24 Jan 25 | Mostafa Adam S. | Common Stock | Sell | Dispose S | No | Yes | 0.454 | 74,773 | 33.95 k | 0 |
24 Jan 25 | Mark Baldry | Common Stock | Sell | Dispose S | No | Yes | 0.4541 | 29,159 | 13.24 k | 94,123 |
24 Jan 25 | Arbet-Engels Christophe | Common Stock | Sell | Dispose S | No | Yes | 0.4546 | 11,624 | 5.28 k | 14,207 |
23 Jan 25 | Mary DiBiase | Common Stock | Grant | Acquire A | No | No | 0 | 61,178 | 0.00 | 513,238 |
23 Jan 25 | Ragan Paula | Common Stock | Grant | Acquire A | No | No | 0 | 169,940 | 0.00 | 1,163,859 |
23 Jan 25 | Mostafa Adam S. | Common Stock | Grant | Acquire A | No | No | 0 | 74,773 | 0.00 | 74,773 |
23 Jan 25 | Mark Baldry | Common Stock | Grant | Acquire A | No | No | 0 | 74,773 | 0.00 | 123,282 |
23 Jan 25 | Arbet-Engels Christophe | Common Stock | Grant | Acquire A | No | No | 0 | 25,831 | 0.00 | 25,831 |